Abstract
The Galα1‐3Galβ (αGal) hapten is xenogeneic for humans; natural anti‐αGal antibodies are present in human serum. To study the possible abnormal expression of the αGal in humans and the pathophysiological role of antibodies, the method of affinity purification of human anti‐αGal IgG was developed. The specificity of antibodies was evaluated using polyacrylamide (PAA)‐based glycoconjugates in direct and competitive enzyme‐linked immunosorbent assays (ELISA). The purified antibodies exhibited αGal‐restricted specificity. The IC50 value for αGal‐PAA was equal to 4 × 10−8 M. In a competitive assay, the Galα1‐3(Fucα1–2)Galβ‐PAA (trisaccharide of blood group B) was found to be one hundred times less active inhibitor than αGal‐PAA. The multivalent αGal‐PAA was 1100 times more potent an inhibitor than the monovalent spacered αGal‐saccharide. The antibodies did not show any reactivity to the negatively charged antigens (DNA, human tumor‐derived mucins). At a concentration of 2 µg/mL, the antibodies agglutinated rabbit erythrocytes but not hare erythrocytes. The high reactivity of antibodies to the αGal‐glycosphingolipids of rabbit erythrocytes and the pig kidney was shown by a modified sensitive method of thin‐layer chromatography with immunodetection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
